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Introduction
Alzheimer disease (AD) is characterized by the extracellular cortical
deposition of senile plaques, the main component of which is a set
of poorly soluble peptides named amyloid -peptides (A).
Mutations in the -amyloid precursor protein (APP) and presenilin
(PS) 1 and PS2, are responsible for early onset and aggressive forms
of AD (Tanzi, 1999) and both perturb the processing of APP,
yielding modified levels of A-like peptides (Checler, 1995). These
considerations explain efforts aimed at identifying the enzymes
responsible for A genesis, because theoretically, any
pharmacological compound that could interfere with A production
could arrest AD pathology or slow down its progression.
A derives from the subsequent proteolytic attack of its
transmembrane precursor APP by - and -secretases (Checler,
1995). -secretase refers to both presenilin-dependent (De
Strooper et al., 1998) and presenilin-independent activities
(Armogida et al., 2001; Beglopoulos et al., 2004; Lai et al., 2006;
Wilson et al., 2003; Wilson et al., 2002; Yagishita et al., 2008).
The former exists in a high molecular weight complex composed
of at least PS1 or PS2, PEN-2 (PSENEN), APH-1 and nicastrin
(NCSTN) (Edbauer et al., 2003; Francis et al., 2002; Goutte et
al., 2000; Herreman et al., 2000; Takasugi et al., 2003; Yu et al.,
2000; Zhang et al., 2000), where each of these proteins behaves
as a limiting factor for the build-up of a biologically active -
secretase complex.
The corollary of such a stringent contribution of each of these
proteins to the -secretase complex is that an important effort should
be made to gain a better understanding of the regulation of their
expression. Studies on the post-transcriptional regulation of the
levels of the various members of the complex have investigated
their catabolic fate. Clearly, proteins are stabilized when they are
included in the complex, whereas the lack of one member apparently
drastically accelerates the catabolism of the others. Thus, lowering
APH1 expression using a siRNA approach clearly reduces presenilin
expression (Lee et al., 2002), and expression of PEN-2 is drastically
lowered in presenilin- and nicastrin-deficient fibroblasts (Dunys et
al., 2006; Zhang et al., 2005).
Very little is known concerning the transcriptional regulation of
the members of the -secretase complex. Here, we establish that
presenilins regulate p53-dependent activation of the Pen2 promoter
via the production of the APP intracellular domain (AICD).
Results
Presenilins regulate the transactivation of the Pen2 promoter
As was consistently reported in previous studies (Bergman et al.,
2004; Crystal et al., 2004; Dunys et al., 2006), PEN-2 expression
The senile plaques found in the brains of patients with
Alzheimer’s disease are mainly due to the accumulation of
amyloid -peptides (A) that are liberated by -secretase, a high
molecular weight complex including presenilins, PEN-2, APH-
1 and nicastrin. The depletion of each of these proteins disrupts
the complex assembly into a functional protease. Here, we
describe another level of regulation of this multimeric protease.
The depletion of both presenilins drastically reduces Pen2
mRNA levels and its promoter transactivation. Furthermore,
overexpression of presenilin-1 lowers Pen2 promoter
transactivation, a phenotype abolished by a double mutation
known to prevent presenilin-dependent -secretase activity.
PEN-2 expression is decreased by depletion of -amyloid
precursor protein (APP) and increased by the APP intracellular
domain (AICD). We show that AICD and APP complement for
Pen2 mRNA levels in APP/APLP1-2 knockout fibroblasts.
Interestingly, overexpression of presenilin-2 greatly increases
Pen2 promoter transactivation. The opposite effect triggered
by both presenilins was reminiscent of our previous study, which
showed that these two proteins elicit antagonistic effects on p53.
Therefore, we examined the contribution of p53 on Pen2
transcription. Pen2 promoter transactivation, and Pen2mRNA
and protein levels were drastically reduced in p53–/– fibroblasts.
Furthermore, PEN-2 expression could be rescued by p53
complementation in p53- and APP-deficient cells. Interestingly,
PEN-2 expression was also reduced in p53-deficient mouse
brain. Overall, our study describes a p53-dependent regulation
of PEN-2 expression by other members of the -secretase
complex, namely presenilins.
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is drastically reduced by the depletion of both PS1 and PS2 in
fibroblasts (Fig. 1A). We examined whether part of this phenotype
could be accounted for by reduced Pen2 gene transcription. Indeed,
we established that presenilin-depleted fibroblasts displayed a
significant reduction of Pen2 promoter transactivation (Fig. 1B) and
mRNA levels (Fig. 1C), indicating that reduced transcription of the
Pen2 promoter could also potentially contribute to the lowered levels
of PEN-2 in these cells. Interestingly, PEN-2 protein levels in
presenilin–/– fibroblasts could be enhanced by complementation with
both PS1 and PS2 (Fig. 1D).
We examined whether PS1 and PS2 similarly influenced Pen2
promoter transactivation. Interestingly, PS1 and PS2 elicited
opposing effects. Thus, as was previously described (Alves da Costa
et al., 2002; Alves da Costa et al., 2006; Kang et al., 2005), PS1
overexpression reduced PS2 expression (Fig. 2A), which was
accompanied by a reduction of Pen2 promoter transactivation (Fig.
2B). Conversely, PS2 overexpression reduced PS1 levels (Fig. 2A)
and drastically enhanced Pen2 promoter transactivation (Fig. 2B).
Conversely, PS2 depletion decreased Pen2 mRNA levels (Fig. 2C)
whereas depletion of PS1 did not significantly affect them.
Presenilin-dependent -secretase controls Pen2 promoter
transactivation via AICD
To investigate the role of presenilin-dependent -secretase activity
in the regulation of Pen2 promoter transcription, we analyzed the
effect of the substitution of aspartate residues 257 and 385 of PS1
by alanines. This double mutation (DD-PS1) has been reported to
abolish PS1-associated -secretase activity (Wolfe et al., 1999). Fig.
2B shows that this double mutation prevented the PS1-induced
inhibition of Pen2 promoter transactivation, suggesting a role of a
-secretase-derived product in the control of Pen2 transcriptional
regulation. Two distinct lines of evidence suggest that this product
could be AICD, the intracellular domain of APP that is released
upon cleavage of APP by -secretase (Passer et al., 2000). First,
the overexpression of AICD59 (C59 in Fig. 3A) increases Pen2
promoter transactivation (Fig. 3A, lower panel). Second, fibroblasts
devoid of APP display reduced PEN-2 expression (Fig. 3B), and
lowered Pen2 promoter activation (Fig. 3C) and mRNA levels (Fig.
3D). Importantly, we established that the transfection of APP,
AICD50 (C50) or AICD59 cDNA in APP/APLP2-deficient
fibroblasts rescued the levels of Pen2 mRNA (Fig. 3E). Overall,
this suggests that the lack of endogenous AICD probably accounts
for the reduced Pen2 promoter activation, mRNA levels and
expression in APP-deficient fibroblasts.
p53 regulates Pen2 promoter transactivation
We envisioned the possibility that presenilin-dependent and AICD-
induced regulation of Pen2 promoter transactivation could be
mediated by p53 for two main reasons. First, the opposite effects
of PS1 and PS2 on the transactivation of the Pen2 promoter were
strikingly similar to those triggered by these proteins on p53
expression, activity, promoter transactivation and mRNA levels
(Alves da Costa et al., 2006). Second, we previously demonstrated
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Fig. 1. The depletion of both PS1 and PS2 lowers PEN-2 expression,
decreases the transactivation of its promoter and reduces mRNA levels.
(A)Endogenous PEN-2 and -tubulin (loading control) immunoreactivity
were analyzed in wild-type (PS+/+) and presenilin-deficient fibroblasts (PS–/–)
by western blot, using antibodies against PEN-2, the N-terminus of PS1 (PS1
N-ter) and the C-terminus of PS2 (PS2 C-ter). (B)Human Pen2 promoter
(hpPen-2) transactivation was analyzed in the indicated cell lines. Bars are the
means ± s.e.m. of 15 independent determinations and are expressed as a
percentage of control PS+/+ fibroblasts. P-value compares luciferase activity
with that obtained in PS+/+ cells. (C)Pen2 mRNA levels were monitored in the
indicated cell lines. Bars represent the means ± s.e.m. of six independent
experiments. (D)PS–/– fibroblasts were transfected with both PS1 and PS2
cDNA. Endogenous PEN-2 expression was assessed as above with PEN-2
antibody, and transfection efficiencies were established using anti-PS1-Nter
and anti-PS2-Cter antibodies, respectively.
Fig. 2. Overexpression of PS1 and PS2 triggers opposite effects on PEN-2
expression and Pen2 promoter transactivation. (A)Stably transfected HEK293
cells overexpressing empty cDNA (Mock), PS1 or PS2 were analyzed for PS1
and PS2 expression, as well as for endogenous PEN-2 immunoreactivity by
western blot using anti-PS1-Nter, anti-PS2-Cter and PNT2 antibodies,
respectively. (B)Stably transfected HEK293 cells overexpressing empty
cDNA (Mock), wild-type PS1 (wtPS1), Asp257rAla/Asp385rAla-PS1 (DD
PS1) or wild-type PS2 were cotransfected with both Pen2 promoter luciferase
(hpPen-2-luciferase) and -galactosidase (to normalize the transfection
efficiencies) reporter gene constructs then Pen2 promoter transactivation was
measured. Bars are the means ± s.e.m. of eight independent determinations.
P-values compare luciferase activity with that obtained in mock-transfected
cells. (C)Pen2 mRNA levels were monitored in the indicated fibroblast
knockout cell lines. Bars represent the means ± s.e.m. of six independent
experiments. ns, not significant.
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that AICD could indeed act as a transcriptional regulator of p53
(Alves da Costa et al., 2006). Four lines of independent data support
the view that p53 is responsible for the presenilin-associated
regulation of Pen2 promoter transactivation. First, PEN-2 expression
(Fig. 4A,B), promoter transactivation (Fig. 4C) and quantitative real-
time PCR measurements of Pen2 mRNA levels (Fig. 4D) were all
drastically reduced by depletion of endogenous p53. Second, PEN-
2 expression was also reduced in p53-deficient mouse brain (Fig.
4E,F). Third, the transient transfection of p53 cDNA in p19Arf–/–
p53–/– fibroblasts restores PEN-2 expression (Fig. 5A,B) and
promoter activation (Fig. 5C). Fourth, p53 cDNA transfection also
increases PEN-2 expression in APP-deficient fibroblasts (Fig. 5D).
To confirm the association between AICD-induced upregulation
of Pen2 promoter transactivation and p53, we examined the
influence of the depletion of endogenous p53 on the AICD-
associated phenotype. Clearly, AICD increased Pen2 mRNA levels
in p19Arf–/– cells but this effect was fully abolished by the lack of
endogenous p53 (Fig. 5E), thereby confirming the fact that AICD-
induced upregulation of Pen2 promoter transactivation was fully
mediated by p53 (Fig. 5E). Overall, our data demonstrate for the
first time that p53 is a regulator of Pen2 promoter transactivation
and indicate that presenilins could modulate Pen2 transcription via
AICD-mediated control of this oncogene.
Discussion
Protein homeostasis results from a complex set of cellular
regulations, implying the involvement of both genesis and
catabolism. Most neurodegenerative diseases are associated with
increased levels of proteins that are prone to aggregation, giving
rise to intracellular or extracellular lesions thought to be involved
in the degenerative processes (Bucciantini et al., 2002). This is true
in Alzheimer disease, where both extracortical lesions, called senile
plaques, and intracellular accumulation of abnormally
phosphorylated tau protein are observed at a late stage of the disease
(Selkoe, 1991).
The biology of the presenilin-dependent -secretase, the
enzymatic machinery that generates A peptides, is poorly
understood, although several cell biology studies emphasize the
crucial role of each of the proteins in the build-up of the complex
and reveal a highly coordinated sequence of events. This implies
Fig. 3. Influence of AICD and APP on PEN-2 expression, promoter
transactivation and mRNA levels. (A)Mock-transfected HEK293 cells were
transiently transfected with empty pcDNA3 vector or AICD (C59) then C59
expression (upper panel) and Pen2 promoter transactivation (lower panel)
were measured. Bars are the means ± s.e.m. of six independent determinations
and are expressed as control luciferase activity (taken as 100) obtained in
mock-transfected cells. P-value compares luciferase activity with that obtained
in mock-transfected cells. (B)Endogenous PEN-2 and -actin (loading
control) immunoreactivities were analyzed by western blot in wild-type (WT)
and APP-deficient (APP–/–) fibroblasts. Bars represent densitometric analyses
of endogenous PEN-2 immunoreactivity in five independent experiments and
are expressed as a percentage of PEN-2 expression recovered in WT
fibroblasts. (C)Pen2 promoter transactivation was analyzed in the indicated
cell lines. Bars are the means ± s.e.m. of three independent determinations. P-
value compares luciferase activity with that obtained in WT fibroblasts.
(D)Pen2 mRNA levels were monitored in the indicated cell lines. Bars
represent the means ± s.e.m. of six independent experiments. (E)APP/APLP2-
deficient fibroblasts were transiently transfected with empty vector (DNA3) or
the indicated cDNAs then Pen2 mRNA levels were quantified. Bars represent
the means ± s.e.m. of three independent experiments.
Fig. 4. PEN-2 expression, promoter transactivation and mRNA levels are
decreased by p53 deficiency, in vitro and in vivo. Fibroblasts deficient for
p19Arf (p19Arf–/–) or for both p19Arf and p53 (p19Arf–/– p53–/–) were analyzed
for their endogenous PEN-2 content (A,B). Panel B represents the
densitometric analysis of PEN-2 immunoreactivity expressed as percentage of
control expression observed in p19Arf–/– fibroblasts and are the means ± s.e.m.
of four independent experiments. (C,D)Pen2 promoter activation (C) and
Pen2 mRNA levels (D) were monitored using the human Pen2 promoter-
luciferase reporter gene construct and by real-time quantitative PCR. Bars are
the means ± s.e.m. of nine (C) and 3-4 (D) independent determinations. P-
values compare p19Arf–/– p53–/– and p19Arf–/– fibroblasts. (E,F)Analysis (E)
and quantification (F) of PEN-2 expression in wild-type (Wt) and p53-
deficient mouse brains. Bars are the means ± s.e.m. of four determinations.
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that the level of each of the components can be seen as rate-limiting
step for -secretase formation and therefore conditions the resulting
phenotypes (Edbauer et al., 2003; Kimberly et al., 2003; Takasugi
et al., 2003).
Several studies suggest that the catabolism of the members of
the -secretase complex is drastically enhanced when proteins occur
outside of the complex. Thus, reduction of APH-1 leads to drastic
reduction of presenilin expression (Lee et al., 2002). A few works
have suggested that the catabolism of the members of the complex
can be regulated by proteasomal degradation (Bergman et al., 2004;
Crystal et al., 2004), but a recent study indicated that these
observations probably result from an artifactual effect of proteasome
inhibitors that could nonspecifically upregulate CMV-driven
promoter transcription (Dunys et al., 2006).
Relatively little data concern upstream regulation of these
proteins and particularly the fact that they might be modulated at
a transcriptional level. Previous studies have demonstrated the
regulation of PSEN1 promoter transcription by ETS proteins,
particularly Elk-1 and ER81 (Pastorcic and Das, 2000; Pastorcic
and Das, 2003), cAMP-response element-binding protein (CREB)
(Mitsuda et al., 2001) or p53 (Pastorcic and Das, 2000; Roperch et
al., 1998). The transcription of PSEN2 involves Sp1 and Egr-1
(Renbaum et al., 2003). Recently, APH1A and Pen2 promoter
sequences have been described (Wang et al., 2006b). The APH1A
promoter seems to be regulated by HIF-1 under hypoxic conditions
(Wang et al., 2006b), whereas the Pen2 promoter contains CREB-
binding domains (Wang et al., 2006a). Until now, the sequence of
the nicastrin gene promoter was unknown and its transcriptional
regulation has not been documented.
Our study clearly establishes that PS1 and PS2 modulate Pen2
promoter transactivation by a p53-dependent mechanism (Fig. 6).
Thus, depletion of presenilin reduces Pen2 gene expression,
promoter activation and mRNA levels. This effect is related to
presenilin-associated catalytic activity, because it is prevented by
a double mutation known to abolish -secretase activity. This
phenotype was apparently due to a -secretase-derived product of
APP because depletion of endogenous APP mimics that triggered
by the deficiency of both PS1 and PS2 on PEN-2 protein and mRNA
levels as well as Pen2 promoter transactivation. That this product
corresponded to AICD was supported by our demonstration that
AICD-induced upregulation of Pen2 promoter transactivation was
fully abolished by the depletion of endogenous p53. These results
agree perfectly with our previous demonstration that AICD acts as
a transcriptional regulator of p53 (Alves da Costa et al., 2006), as
demonstrated for various other proteins (Baek et al., 2002; Kim et
al., 2003; Pardossi-Piquard et al., 2005; von Rotz et al., 2004; Zhang
et al., 2007). This is the first demonstration that p53 can upregulate
Pen2 transcription.
The question arose as to whether p53 directly modulates Pen2
transcription. This appears unlikely because we did not delineate
any in silico consensus sequences corresponding to putative sites
targeted by p53. Another possibility could be that NFB, which
lowers p53 activity (Ozes et al., 1999), could be downregulated,
but it has been reported that NFB did not modulate Pen2
promoter transactivation (Wang et al., 2006a). Finally, we
envisioned the possibility that p53 could lead to a CREB-
associated increase of Pen2 transcription because CREB was
reported to activate Pen2 promoter transactivation (Wang et al.,
2006a). However, our data indicate that endogenous p53
downregulates CREB transcriptional activity in opposition to the
p53-induced increase of Pen2 transcription (data not shown).
Altogether, this indicates that p53 indirectly controls Pen2
promoter transactivation via a molecular intermediate that remains
to be identified.
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Fig. 5. p53 complementation increases PEN-2 expression and promoter
transactivation in p19Arf–/– p53–/– and APP–/– fibroblasts. (A-C)p19Arf–/– p53–/–
fibroblasts were transiently transfected with empty pcDNA3 vector (DNA3) or
p53 cDNA, then PEN-2 expression (A,B) or promoter transactivation (C) were
analyzed. Bars are the means ± s.e.m. of 3-5 (B) or four (C) independent
determinations. P-values compare PEN-2 expression or luciferase activity with
those observed in mock-transfected p19Arf–/– p53–/– fibroblasts. (D)APP-
deficient fibroblasts were transfected with empty vector (DNA3) or p53 cDNA
then PEN-2 expression was monitored. (E)The indicated fibroblastic cell line
was transfected with empty pcDNA3 or C59 then Pen2 mRNA levels were
monitored. Bars are the means ± s.e.m. of four independent determinations. ns,
not significant
Fig. 6. Schematic representation of regulation between presenilins, p53 and
PEN-2. Scheme of the pathway linking PS1, PS2, AICD, p53 and PEN-2. As
we previously described (Alves da Costa et al., 2006), PS1 lowers the level of
p53 whereas PS2 increases p53. Both proteins functionally interact, but PS2 is
dominant for the p53-dependent pro-apoptotic phenotype (PS2>>PS1) (Alves
da Costa et al., 2006). AICD positively modulates p53 (Alves da Costa et al.,
2006) and p53 increases Pen2 transcription (present study). Conversely, there
exists a feedback loop by which PEN-2 downregulates p53 (Dunys et al.,
2007).
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It is interesting to emphasize the fact that PS1 and PS2 trigger
opposite effects on PEN-2 protein level and Pen2 promoter
transactivation. PS1 overexpression lowers PEN-2 protein
expression whereas PS2 exacerbates its expression. In agreement
with these data, PS2 depletion diminished Pen2 mRNA levels. These
observations fit perfectly with the opposite influence of PS1 and
PS2 on p53 (Alves da Costa et al., 2006; Kang et al., 2005) and
indirectly confirm that p53 accounts for the distinct and opposite
effects of PS1 and PS2 on PEN-2 levels. Furthermore, this scheme
suggests two distinct loops of regulation of PS1 (anti-apoptotic)
and PS2 (pro-apoptotic) phenotypes. Previous studies have
demonstrated that PS1 lowers p53 (Mitsuda et al., 2001; Roperch
et al., 1998), whereas PS2 increases the expression of this oncogene
(Alves da Costa et al., 2002; Alves da Costa et al., 2006; Janicki
and Monteiro, 1997; Nguyen et al., 2005). The opposite phenotype
triggered by PS1 and PS2 adds support to previous studies
suggesting that these proteins could indeed display their own
function and elicit their specific pharmacological spectrum, some
of them could be linked to p53-dependent functions unrelated to
the control of cell death (Chen et al., 2003; Gu et al., 2004; Lai et
al., 2003).
The present study has several conceptual implications. First, this
work identifies p53 as a common effector modulating the
transcriptional regulation of various members of the -secretase
complex. Second, this is the first indication that a member of the
-secretase complex could participate in the transcriptional
regulation of another member of this complex. Third, we
demonstrate that PS1 and PS2 distinctly influence PEN-2 via an
AICD- and p53-dependent mechanism, suggesting that the generic
term of -secretase probably refers to various complexes with
specific composition harboring various pharmacological functions.
Overall, this study shows that proteins of the complex are not only
associated with post-tranductional events but could also be
intimately linked to upstream events, implying a transcriptional
control of their expression by p53 via AICD-dependent mechanisms.
Materials and Methods
Cell culture and transfection
Stably transfected HEK293 cells expressing wild-type (wt) PS1, mutated
D257A/D385A PS1 or wt PS2 were obtained after transfection of 3 g cDNA using
Lipofectamine reagent (Invitrogen) according to the manufacturer’s recommendations
and selection of positive transfectants by western blot as described below. Fibroblasts
were transfected with Lipofectamine 2000 reagent (Invitrogen) or JetPEI reagent
(Polyplus-transfections) according to the manufacturer’s recommendations. In some
experiments, fibroblasts were transfected by means of the mouse embryonic fibroblasts
NucleofectorTM kit (Amaxa Biosystems, Cologne, Germany) as described (Alves da
Costa et al., 2006). Mouse embryonic fibroblasts (MEFs) depleted of PS1 (PS1–/–),
PS2 (PS2–/–), PS1 and PS2 (PS–/–) or APP (APP–/–) were cultured as previously
described (Alves da Costa et al., 2006; Dunys et al., 2006). MEFs devoid of p19Arf–/–
or of both p19Arf–/– and p53–/– were cultured as previously described (Dunys et al.,
2007). These two cell lines allow monitoring the influence of p53 without interference
with p53-associated p19Arf-dependent control of cell cycle (Kamijo et al., 1998).
Telencephalon-specific murine cells (TSM-1) overexpressing Myc-tagged PEN-2 were
obtained and cultured as previously described (Dunys et al., 2006).
Site-directed mutagenesis.
PS1 construct in which both aspartates D285 and D357 were replaced by an alanine
residue (DD-PS1) was obtained by oligonucleotide-directed mutagenesis from human
wild-type PS1 cDNA by means of a QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA). Mutagenesis was performed according to manufacturer’s
conditions using the set of primers: 5-GGC TGT GAT TTC AGT ATA TGC TTT
AGT GGC TGT TTT GTG TCC G-3 and 5-CGG ACA CAA AAC AGC CAC
TAA AGC ATA TAC TGA AAT CAC AGC C-3 (Cybergene, Saint-Malo, France)
containing the D257A mutation. Then, this mutant construct was used to produce the
double mutant using the primers: 5-CTT GGA TTG GGA GCT TTC ATT TTC TAC
AGT GTT CTG G-3 and 5-CCA GAA CAC TGT AGA AAA TGA AAG CTC
CCA ATC CAA G-3 containing the D385A mutation. Final cDNA constructs were
entirely sequenced to verify mutations.
Western blot analyses and antibodies
Cells were gently scraped with PBS-EDTA 5 mM, pelleted by centrifugation, and
then lysed in 50-100 l of 25 mM HEPES, pH 7.5 containing a cocktail of protease
inhibitors (Roche Molecular Biochemicals). Protein analyses in brains from 3-month-
old wild-type or p53-knockout mice were carried out after homogenization in 10 mM
Tris-HCl (pH 7.5) or in Prüsiner buffer (50 mM Tris-HCl, pH 7.5, containing 150
mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate). Equal amounts
of proteins were separated on SDS-PAGE gels containing 8-12% acrylamide
(Euromedex) for analysis of APP, PS1 and PS2 or on 16.5% acrylamide Tris-Tricine
gels for PEN-2. Proteins were then wet-transferred to Hybond C membranes (GE
HealthCare). Membranes were blocked with non-fat milk and incubated overnight
at 4°C with the following primary antibodies: anti-PEN-2 (PNT2, rabbit polyclonal,
Calbiochem; 1:1000), anti-actin (mouse monoclonal, Sigma; 1:5000), anti-PS1-Nter
(rabbit polyclonal, a gift from Gopal Thinakaran, University of Chicago, IL; 1:1000),
anti-PS2-Cter 2192 (rabbit polyclonal, Cell Signaling; 1:1000) and anti-APP 22C11
(mouse monoclonal, Boehringer; 1:1000). Immunological complexes were revealed
by enhanced electrochemiluminescence (Roche Molecular Biochemicals) with either
anti-rabbit or anti-mouse IgG antibodies (1:5000) coupled to peroxidase (Jackson
ImmunoResearch).
Real-time quantitative polymerase chain reactions
RNAs from fibroblastic cell lines were extracted by means of the RNeasy kit (Qiagen,
Hilden, Germany) according to the manufacturer’s recommendations and treated with
DNase I and 2 g of total RNA were reverse transcribed as previously described
(Alves da Costa et al., 2006). Real-time PCR was performed as described (Dunys et
al., 2007) with gene-specific primers for mouse Pen2 and mouse -actin to normalize
mRNA concentrations.
Promoter activity measurements
The human Pen2 promoter (hpPen-2) in frame with luciferase reporter gene has been
previously described (Mitsuda et al., 1997; Renbaum et al., 2003; Wang et al., 2006a).
Cells were grown in 12-well plates until they reach 60-70% confluency and were
then cotransfected with 1 g Pen2-luciferase cDNA and 0.5 g of a -galactosidase
transfection vector (to normalize transfection efficiency) with or without 1 g of
either pcDNA3, AICD59, AICD50 or p53 cDNA by means of the Lipofectamine
2000 reagent (Invitrogen) or the Amaxa Transfection System (Amaxa Biosystems)
according to the manufacturer’s protocol. Luciferase and -galactosidase activities
were then analyzed (Promega).
Statistical analysis
Statistical analyses were performed using Prism Software (Graphpad Software, San
Diego, CA) by the mean of the Neuman-Keuls multiple comparison test.
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